C. Cooper

470 total citations
21 papers, 337 citations indexed

About

C. Cooper is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, C. Cooper has authored 21 papers receiving a total of 337 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hepatology, 8 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in C. Cooper's work include Hepatitis C virus research (14 papers), Liver Disease Diagnosis and Treatment (5 papers) and HIV/AIDS drug development and treatment (5 papers). C. Cooper is often cited by papers focused on Hepatitis C virus research (14 papers), Liver Disease Diagnosis and Treatment (5 papers) and HIV/AIDS drug development and treatment (5 papers). C. Cooper collaborates with scholars based in Canada, United States and United Kingdom. C. Cooper's co-authors include Marina B. Klein, M. John Gill, Joseph Cox, Sahar Saeed, Sharon Walmsley, Hong Yang, Richard Larouche, Mark Tyndall, Mark Sulkowski and David Haase and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Hepatology and International Journal of Epidemiology.

In The Last Decade

C. Cooper

21 papers receiving 329 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Cooper Canada	12	246	244	132	47	18	21	337
Deborah D. Brown United States	4	376 1.5×	334 1.4×	177 1.3×	34 0.7×	11 0.6×	5	450
Juan González Spain	7	285 1.2×	355 1.5×	223 1.7×	63 1.3×	61 3.4×	14	467
Laura Benítez‐Gutiérrez Spain	13	310 1.3×	278 1.1×	148 1.1×	49 1.0×	19 1.1×	20	414
Charlotte H. S. B. van den Berg Netherlands	9	220 0.9×	256 1.0×	88 0.7×	34 0.7×	6 0.3×	15	301
Leonor Moreno Spain	7	206 0.8×	188 0.8×	110 0.8×	43 0.9×	34 1.9×	9	265
Ana Arizcorreta Spain	7	382 1.6×	316 1.3×	108 0.8×	44 0.9×	49 2.7×	12	428
Andrea Bregenzer Switzerland	8	289 1.2×	305 1.3×	166 1.3×	43 0.9×	42 2.3×	16	384
Kelly Wroblewski United States	5	204 0.8×	214 0.9×	70 0.5×	35 0.7×	3 0.2×	10	283
Julio Sola Spain	6	183 0.7×	227 0.9×	188 1.4×	68 1.4×	28 1.6×	8	302
Laveeza Bhatti United States	11	158 0.6×	127 0.5×	132 1.0×	41 0.9×	33 1.8×	20	276

Countries citing papers authored by C. Cooper

Since Specialization

Citations

This map shows the geographic impact of C. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Cooper more than expected).

Fields of papers citing papers by C. Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Cooper. The network helps show where C. Cooper may publish in the future.

Co-authorship network of co-authors of C. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of C. Cooper. A scholar is included among the top collaborators of C. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Cooper. C. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Younossi, Zobair M., Maria Stepanova, Ira M. Jacobson, et al.. (2017). High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4. Journal of Hepatology. 66(1). S114–S114. 1 indexed citations

Puoti, Massimo, Heiner Wedemeyer, C. Cooper, et al.. (2017). Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials. Journal of Hepatology. 66(1). S514–S514. 11 indexed citations

Brown, Robert S., Massimo Puoti, C. Cooper, et al.. (2015). LP39 : Implications of baseline HCVRNA level and intrapatient viral load variability on OBV/PTV/R + DSV 12-week treatment outcomes. Journal of Hepatology. 62. S283–S283. 3 indexed citations

Cooper, C., Susanna Naggie, M. S. Saag, et al.. (2015). P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study. Journal of Hepatology. 62. S675–S676. 3 indexed citations

Klein, Marina B., Jim Young, David Dunn, et al.. (2014). The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study. CMAJ Open. 2(4). E318–E329. 14 indexed citations

Cooper, C. & Marina B. Klein. (2014). HIV/hepatitisCvirus coinfection management: changing guidelines and changing paradigms. HIV Medicine. 15(10). 621–624. 2 indexed citations

Puoti, Massimo, C. Cooper, Thomas Berg, et al.. (2014). ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials. Queen Mary Research Online (Queen Mary University of London). 11 indexed citations

Cooper, C.. (2012). Hepatitis C Treatment Highlights From the 2011 American Association for the Study of Liver Disease Meeting. Clinical Infectious Diseases. 55(3). 418–425. 6 indexed citations

Hull, Mark, Adefowope Odueyungbo, Sahar Saeed, et al.. (2012). Factors Associated With Discordance Between Absolute CD4 Cell Count and CD4 Cell Percentage in Patients Coinfected With HIV and Hepatitis C Virus. Clinical Infectious Diseases. 54(12). 1798–1805. 15 indexed citations

10.

Pockros, Paul J., Dorte Møller Jensen, Renea A. Taylor, et al.. (2012). 1205 SVR-12 AMONG G1/4 TREATMENT-NAIVE PATIENTS RECEIVING MERICITABINE IN COMBINATION WITH PEG-IFNa-2A/RBV: INTERIM ANALYSIS FROM THE JUMP-C STUDY. Journal of Hepatology. 56. S477–S478. 12 indexed citations

11.

Mallolas, Josep, Stanislas Pol, C. Cooper, et al.. (2012). Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients [abstract LB-37]. 4 indexed citations

12.

Everson, Greg, C. Cooper, Christophe Hézode, et al.. (2012). 1177 RAPID AND SUSTAINED ACHIEVEMENT OF UNDETECTABLE HCV RNA DURING TREATMENT WITH RITONAVIR-BOOSTED DANOPREVIR/PEG-IFNa-2A/RBV IN HCV GENOTYPE 1 OR 4 PATIENTS: DAUPHINE WEEK 12 INTERIM ANALYSIS. Journal of Hepatology. 56. S466–S466. 16 indexed citations

13.

Mallolas, Josep, Stanislas Pol, Antonio Rivero, et al.. (2012). 50 BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN FOR THE TREATMENT OF HCV/HIV CO-INFECTED PATIENTS: END OF TREATMENT (WEEK 48) INTERIM RESULTS. Journal of Hepatology. 56. S22–S22. 22 indexed citations

14.

Pockros, Paul J., Dorte Møller Jensen, Ryan M. Taylor, et al.. (2011). 1359 FIRST SVR DATA WITH THE NUCLEOSIDE ANALOGUE POLYMERASE INHIBITOR MERICITABINE (RG7128) COMBINED WITH PEGINTERFERON/RIBAVIRIN IN TREATMENT-NAIVE HCV G1/4 PATIENTS: INTERIM ANALYSIS FROM THE JUMP-C TRIAL. Journal of Hepatology. 54. S538–S538. 38 indexed citations

15.

Vierling, John M., E.J. Lawitz, F. Poordad, et al.. (2011). 481 FOUR-WEEK THERAPY WITH PEGINTERFERON ALFA-2B/ RIBAVIRIN EFFECTIVELY PREDICTS SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE AND PREVIOUS-TREATMENT-FAILURE PATIENTS WITH HCV-1 TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN. Journal of Hepatology. 54. S197–S197. 4 indexed citations

16.

Klein, Marina B., Sahar Saeed, Hong Yang, et al.. (2009). Cohort Profile: The Canadian HIV-Hepatitis C Co-infection Cohort Study. International Journal of Epidemiology. 39(5). 1162–1169. 73 indexed citations

17.

Powis, Jeff, Kevork Peltekian, Shoei‐Sheng Lee, et al.. (2007). Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3. Journal of Viral Hepatitis. 15(1). 52–57. 28 indexed citations

18.

Cooper, C., et al.. (2007). Once‐daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Medicine. 8(1). 1–7. 30 indexed citations

19.

Chuansumrit, Ampaiwan, Alex John London, Arthur R. Thompson, et al.. (2006). Ethical issues in haemophilia. Haemophilia. 12(s3). 30–35. 14 indexed citations

20.

Cooper, C., et al.. (2005). Clinical outcomes of first antiretroviral regimen in HIV/hepatitis C virus co‐infection. HIV Medicine. 7(1). 32–37. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact